BR9911324A - Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragility - Google Patents
Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragilityInfo
- Publication number
- BR9911324A BR9911324A BR9911324-4A BR9911324A BR9911324A BR 9911324 A BR9911324 A BR 9911324A BR 9911324 A BR9911324 A BR 9911324A BR 9911324 A BR9911324 A BR 9911324A
- Authority
- BR
- Brazil
- Prior art keywords
- fragility
- compositions
- ghs
- serm
- modulators
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 102000015694 estrogen receptors Human genes 0.000 title 1
- 108010038795 estrogen receptors Proteins 0.000 title 1
- 239000003324 growth hormone secretagogue Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 4- (2-pyrrolidin-1-yl-ethoxy) -phenyl Chemical group 0.000 abstract 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 229940047889 isobutyramide Drugs 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Patente de Invenção: <B>''COMBINAçõES TERAPêUTICAS DE MODULADORES DE RECEPTOR (SELETIVO) DE ESTROGêNIO (SERM) E SECRETAGOGOS DE HORMÈNIO DO CRESCIMENTO (GHS) PARA O TRATAMENTO DE FRAGILIDADE MúSCULO-ESQUELETAL''<D>. Esta invenção refere-se a composições de combinações farmacêuticas e a métodos que contenham (-)-cis-6-fenil-5-(4-(2-pirrolidin-1-il-etóxi)-fenil)-5,6,7,8-tetra-hidronaftale n-2-ol ou um sal farmaceuticamente aceitável dos mesmos e 2-amino-N-(2-(3a(R)-benzil-2-metil-3-oxo-2,3,3a,4,6,7-hexahidro-pira zolo-[4,3-c]piridin-5-il)-1-(R)-benziloximetil-2-oxo-etil)-iso-butiramida ou um sal farmaceuticamente aceitável da mesma, métodos para a utilização de tais composições e kits que contenham tais composições. As composições são úteis para o tratamento de fragilidade músculo-esqueletal, incluindo a osteoporose, a fratura osteoporótica, a fraca massa óssea, a fragilidade e a fraca massa muscular.Invention Patent: <B> '' THERAPEUTIC COMBINATIONS OF ESTROGEN RECEIVER (SELECTIVE) MODULATORS (SERM) AND GROWTH HORMONE (GHS) SECRETAGOGUES FOR TREATING MUSCLE-SKELETAL FRAGILITY '' <D>. This invention relates to pharmaceutical combination compositions and methods containing (-) - cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -5,6,7 , 8-tetrahydronaftale n-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N- (2- (3a (R) -benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyro zolo- [4,3-c] pyridin-5-yl) -1- (R) -benzyloxymethyl-2-oxo-ethyl) -iso-butyramide or a pharmaceutically acceptable salt thereof , methods for using such compositions and kits containing such compositions. The compositions are useful for the treatment of musculoskeletal fragility, including osteoporosis, osteoporotic fracture, weak bone mass, fragility and weak muscle mass.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8946998P | 1998-06-16 | 1998-06-16 | |
| PCT/IB1999/001117 WO1999065486A1 (en) | 1998-06-16 | 1999-06-16 | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9911324A true BR9911324A (en) | 2001-04-03 |
Family
ID=22217825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9911324-4A BR9911324A (en) | 1998-06-16 | 1999-06-16 | Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragility |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1087764A1 (en) |
| JP (1) | JP2002518326A (en) |
| KR (1) | KR20010052852A (en) |
| CN (1) | CN1301160A (en) |
| AP (1) | AP9901582A0 (en) |
| AR (1) | AR018869A1 (en) |
| AU (1) | AU4054799A (en) |
| BG (1) | BG105041A (en) |
| BR (1) | BR9911324A (en) |
| CA (1) | CA2335134A1 (en) |
| CO (1) | CO5070587A1 (en) |
| EA (1) | EA200001186A1 (en) |
| GT (1) | GT199900087A (en) |
| HN (1) | HN1999000097A (en) |
| HR (1) | HRP20000859A2 (en) |
| HU (1) | HUP0102505A3 (en) |
| ID (1) | ID27599A (en) |
| IL (1) | IL138630A0 (en) |
| IS (1) | IS5691A (en) |
| MA (1) | MA26652A1 (en) |
| NO (1) | NO20006312L (en) |
| OA (1) | OA11505A (en) |
| PA (1) | PA8475901A1 (en) |
| PE (1) | PE20000646A1 (en) |
| PL (1) | PL344981A1 (en) |
| SK (1) | SK18912000A3 (en) |
| TN (1) | TNSN99124A1 (en) |
| TR (1) | TR200003544T2 (en) |
| WO (1) | WO1999065486A1 (en) |
| ZA (1) | ZA993975B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000047735A2 (en) * | 1999-02-08 | 2000-08-17 | Mcgill University | NON-HUMAN TRANSGENIC ANIMAL WHOSE GERM CELLS AND SOMATIC CELLS CONTAIN A KNOCKOUT MUTATION IN DNA ENCODING ORPHAN NUCLEAR RECEPTOR ERRalpha |
| DE60124616T2 (en) | 2000-05-08 | 2007-09-13 | Pfizer Products Inc., Groton | Enzymatic cleavage of selective modulators of the estrogen receptor |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| JP2004507502A (en) * | 2000-08-30 | 2004-03-11 | ファイザー・プロダクツ・インク | Sustained release formulation for growth hormone secretagogue |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2006024931A2 (en) * | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| ES2604943T3 (en) | 2007-02-09 | 2017-03-10 | Ocera Therapeutics, Inc. | Ghrelin receptor macrocyclic modulators and procedures for their use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-06-15 HN HN1999000097A patent/HN1999000097A/en unknown
- 1999-06-15 PA PA19998475901A patent/PA8475901A1/en unknown
- 1999-06-15 PE PE1999000528A patent/PE20000646A1/en not_active Application Discontinuation
- 1999-06-15 ZA ZA9903975A patent/ZA993975B/en unknown
- 1999-06-15 AP APAP/P/1999/001582A patent/AP9901582A0/en unknown
- 1999-06-15 AR ARP990102848A patent/AR018869A1/en not_active Application Discontinuation
- 1999-06-16 TN TNTNSN99124A patent/TNSN99124A1/en unknown
- 1999-06-16 ID IDW20002627A patent/ID27599A/en unknown
- 1999-06-16 CN CN99806237A patent/CN1301160A/en active Pending
- 1999-06-16 MA MA25628A patent/MA26652A1/en unknown
- 1999-06-16 PL PL99344981A patent/PL344981A1/en not_active Application Discontinuation
- 1999-06-16 HR HR20000859A patent/HRP20000859A2/en not_active Application Discontinuation
- 1999-06-16 WO PCT/IB1999/001117 patent/WO1999065486A1/en not_active Ceased
- 1999-06-16 GT GT199900087A patent/GT199900087A/en unknown
- 1999-06-16 JP JP2000554366A patent/JP2002518326A/en active Pending
- 1999-06-16 EP EP99923802A patent/EP1087764A1/en not_active Withdrawn
- 1999-06-16 BR BR9911324-4A patent/BR9911324A/en not_active Application Discontinuation
- 1999-06-16 KR KR1020007014186A patent/KR20010052852A/en not_active Ceased
- 1999-06-16 HU HU0102505A patent/HUP0102505A3/en unknown
- 1999-06-16 EA EA200001186A patent/EA200001186A1/en unknown
- 1999-06-16 TR TR2000/03544T patent/TR200003544T2/en unknown
- 1999-06-16 CO CO99037622A patent/CO5070587A1/en unknown
- 1999-06-16 SK SK1891-2000A patent/SK18912000A3/en unknown
- 1999-06-16 IL IL13863099A patent/IL138630A0/en unknown
- 1999-06-16 AU AU40547/99A patent/AU4054799A/en not_active Abandoned
- 1999-06-16 CA CA002335134A patent/CA2335134A1/en not_active Abandoned
-
2000
- 2000-10-20 OA OA1200000290A patent/OA11505A/en unknown
- 2000-10-27 IS IS5691A patent/IS5691A/en unknown
- 2000-12-11 BG BG105041A patent/BG105041A/en unknown
- 2000-12-12 NO NO20006312A patent/NO20006312L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20000646A1 (en) | 2000-08-05 |
| CO5070587A1 (en) | 2001-08-28 |
| TR200003544T2 (en) | 2001-04-20 |
| ID27599A (en) | 2001-04-12 |
| MA26652A1 (en) | 2004-12-20 |
| OA11505A (en) | 2004-05-07 |
| EP1087764A1 (en) | 2001-04-04 |
| GT199900087A (en) | 2000-12-07 |
| PA8475901A1 (en) | 2000-05-24 |
| TNSN99124A1 (en) | 2005-11-10 |
| SK18912000A3 (en) | 2001-10-08 |
| KR20010052852A (en) | 2001-06-25 |
| NO20006312D0 (en) | 2000-12-12 |
| ZA993975B (en) | 2000-12-15 |
| PL344981A1 (en) | 2001-11-19 |
| HN1999000097A (en) | 1999-11-03 |
| HUP0102505A3 (en) | 2002-12-28 |
| CN1301160A (en) | 2001-06-27 |
| AU4054799A (en) | 2000-01-05 |
| WO1999065486A1 (en) | 1999-12-23 |
| BG105041A (en) | 2001-08-31 |
| IS5691A (en) | 2000-10-27 |
| HRP20000859A2 (en) | 2001-04-30 |
| NO20006312L (en) | 2000-12-12 |
| EA200001186A1 (en) | 2001-06-25 |
| JP2002518326A (en) | 2002-06-25 |
| AR018869A1 (en) | 2001-12-12 |
| CA2335134A1 (en) | 1999-12-23 |
| AP9901582A0 (en) | 1999-06-30 |
| HUP0102505A2 (en) | 2001-11-28 |
| IL138630A0 (en) | 2001-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9714155A (en) | Prevention of bone mass loss and replacement by certain prostaglandin agonists. | |
| BR9813028A (en) | Prostaglandin agonists and their use to treat bone disorders | |
| EP0911321A3 (en) | Compounds for the treatment of osteoporosis | |
| BR0309875A (en) | methods and compositions for treating peripheral nervous system disorders and novel compounds useful therefor | |
| BR0100558A (en) | Compositions and methods for treating osteoporosis | |
| IL180603A (en) | 3,4-dihydro-1h-naphthalenones which are selective glucocorticoid receptor modulators | |
| PT1222195E (en) | NEW COMPOUNDS OF TIAZOLO (4,5-D) PYRIMIDINE | |
| AP9801269A0 (en) | Prostaglandin agonists. | |
| CA2360313A1 (en) | Glucocorticoid receptor modulators | |
| BR9911324A (en) | Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragility | |
| BR9911228A (en) | Therapeutic combinations comprising a selective modulator of an estrogen receptor and parathyroid hormone | |
| BR9911357A (en) | Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragility | |
| WO2001080894A3 (en) | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies | |
| BR9908214A (en) | Treatment for follicular lymphomas using lymphotoxin pathway inhibitors (lt) | |
| BR9814403A (en) | "indole derivatives useful for the treatment, among others, of osteoporosis" | |
| IL124828A0 (en) | Hyaluronic acid receptors binding agents and the use thereof | |
| CA2274381A1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 | |
| BR0206844A (en) | Use of gal3 receptor antagonists for the treatment of depression and / or anxiety and compounds used in such methods. | |
| ECSP993020A (en) | COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY | |
| ECSP993021A (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY | |
| TH57984A3 (en) | A therapeutic combination consisting of selective estrogen receptor modulators and parathyroid hormone. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |